M SAFWAT WAHBA: Open Payments
NPI 1821097692 · BRIDGETON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,200 in 133 payments from 15 companies in 2025. Trend: 2023 $1,443 · 2024 $1,545 · 2025 $2,200
Food & beverage: $2,093Education: $107
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 31 | $492 |
| Otsuka America Pharmaceutical, Inc. | 27 | $465 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $450 |
| Alkermes, Inc. | 13 | $184 |
| E.R. Squibb & Sons, L.L.C. | 10 | $167 |
| Neurocrine BioSciences, Inc. | 10 | $155 |
| Lundbeck LLC | 5 | $91 |
| ABBVIE INC. | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
Products named: REXULTI, FANAPT, CAPLYTA, ARISTADA, COBENFY, INGREZZA, VRAYLAR, Auvelity.
Industry payments across MO — which companies pay providers there.
